Ifebemtinib mais garsorasib em câncer colorretal metastático previamente tratado com mutação KRASG12C: um ensaio multicêntrico, randomizado, de fase 1b/2
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The Lancet. Oncology
- Publicado em
- 1 set 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial
Zhengbo Song, Liming Zhu, Ying Liu, Rongbo Lin, Xingya Li, Yongzhong Luo, Yuan Yuan, Huaqiu Shi, Yiping Zhang, Baoyuan Zhang et al.
Descritores MeSH
- Antineoplastic Combined Chemotherapy Protocols
- Mutation
- Colorectal Neoplasms
- Proto-Oncogene Proteins p21(ras)
- Adult
- Middle Aged
- Male
- Aged
- Female
- Humans
Veja também
Estudos relacionados
- A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science
- KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials
- Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
- Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO
- Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer
- Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C